05/07/04 09:00 Oxford Biomedica in licence deal with Viragen for LentiVector gene delivery AFX
Oxford Biomedica in licence deal with Viragen for LentiVector gene delivery
AFX
LONDON (AFX) - Oxford Biomedica PLC said it has entered into a licence agreement with Viragen Inc for its LentiVector gene delivery technology.
The agreement provides Viragen with worldwide exclusive rights to utilize the proprietary LentiVector technology in its collaboration with Roslin Institute (Scotland) to develop Avian Transgenic Technology as a novel platform for the efficient and economical manufacturing of therapeutic proteins in chicken eggs.
Under the agreement, Oxford BioMedica will receive an upfront licence fee and annual maintenance payments, the statement added.
In addition, Oxford BioMedica will receive milestone payments on the achievement of technical goals by Viragen and royalties on commercialisation of the Avian Transgenic Technology.
No other financial details were provided.
newsdesk@afxnews.com
http://www.moneyam.com/action/news/showArticle?id=389728